Please login to the form below

Not currently logged in
Email:
Password:

Anoro

This page shows the latest Anoro news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

pitted it against GSK’s two-drug LAMA/LABA Anoro (umeclidinium/vilanterol). ... Trelegy hasn’t been growing particularly quickly since its approval a year ago in the US, with £37m ($48m) in revenues in the first six months of the year, while Anoro

Latest news

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Bevespi demonstrated non-inferiority to GSK’s Anoro (umeclidinium/vilanterol) on peak forced expiratory volume in one second (FEV1) but did not demonstrate superiority on peak FEV1 or non-inferiority on ... The 24-week trial pitted twice-daily Bevespi

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    GSK claims Trelegy has made the strongest start of any of GSK’s new Ellipta range of respiratory meds, which also includes Relvar/Breo (fluticasone furoate/vilanterol) and Anoro (vilanterol/umeclidinium

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    GSK has been bringing other new COPD therapies to market - including Advair successor Breo/Relvar (fluticasone furoate and vilanterol) and Anoro (umeclidinium bromide and vilanterol) - but with greater competition in the

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    protect its franchise with the launch of new two-drug combinations such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide).

  • GSK's Bexsero vaccine growing fast, despite GSK's Bexsero vaccine growing fast, despite "tight" supply

    The product continued to slide, but newer drugs such as Anoro (vilanterol/umeclidinium bromide), Breo (vilanterol/fluticasone furoate) and new severe asthma therapy Nucala (mepolizumab) more than offset the decline, with

More from news
Approximately 12 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Figure 2 shows the sales of GSK’s respiratory treatment, Anoro Ellipta, across the various availabilities. ... The chart reveals that Anoro Ellipta gets most sales when availability is unrestricted.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics